The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

New England Journal of Medicine

Volumn 336, Issue 3, 1997, Pages 153-162

  Campeau, Lucien ^a   Knatterud, Genell L ^a   Domanski, Michael ^a   Hunninghake, Donald B ^a   White, Carl W ^a   Geller, Nancy L ^a   Rosenberg, Yves ^a  

^a MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; MEVINOLIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOSE RESPONSE; GRAFT OCCLUSION; HUMAN; HYPOLIPEMIA; MAJOR CLINICAL STUDY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RECURRENCE RISK; SAPHENOUS VEIN GRAFT; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; CHOLESTEROL, LDL; CHOLESTYRAMINE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; LIFE TABLES; LOVASTATIN; MALE; MIDDLE AGED; SAPHENOUS VEIN; TREATMENT OUTCOME; WARFARIN;

EID: 0031030620     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701163360301     Document Type: Article

References (34)

1. Barboriak JJ, Batayias GE, Pintar K, Korns ME. Pathological changes in surgically removed aortocoronary vein grafts. Ann Thorac Surg 1976;21: 524-7.
2. Campeau L, Enjalbert M, Lespérance J, Vaislic C, Grondin CM, Bourassa MG. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 1983;68:Suppl II:II-1-II-7.
3. Lie JT, Lawrie GM, Morris GC Jr. Aortocoronary bypass saphenous vein graft atherosclerosis: anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively. Am J Cardiol 1977;40:906-14.
4. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts: morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986;6:594-600.
5. Palac RT, Meadows WR, Hwang MH, Loeb HS, Pifarre R, Gunnar RM. Risk factors related to progressive narrowing in aortocoronary vein grafts studied 1 and 5 years after surgery. Circulation 1982;66:Suppl I:I-40-I-44.
6. Campeau L, Enjalbert M, Lespérance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311:1329-32.
7. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
8. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
9. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
10. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
11. Blankenhorn DH, Azen SP, Kramsch DM, et al Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76.
12. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
13. Haskell WL, Alderman EL, Fair JM, et al. Eftects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
14. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8. [Erratum, Lancet 1994;344:762.]
15. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-9.
16. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
17. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
18. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988;78:Suppl I:I-140-I-143.
19. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-5.
20. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987;295:1309-12.
21. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2835-8.
22. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986;2:933-6.
23. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69.
24. Reiber JHC, van der Zwet PMJ, von Land CD, et al. Quantitative coronary arteriography: equipment and technical requirements: In: Reiber JHC, Serruys PW, eds. Advances in quantitative coronary arteriography. Vol. 137 of Developments in cardiovascular medicine. Dordrecht, the Netherlands: Kluwer Academic, 1993:75-111.
25. Reiber JHC, Serruys PW, Kooijman CJ, et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985;71: 280-8.
26. Lespérance J, Campeau L, Laurier J, et al. Reproducibility (true change) of coronary artery saphenous vein graft measurements using quantitative angiography. Atherosclerosis 1994;109:298. abstract.
27. Syvänne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery: a validation study. Int J Card Imaging 1994;10:243-52.
28. Campeau L, Knatterud GL, White C, et al. The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (POST CABG): angiographic outcomes. In: Bruschke AVG, Reiber JHC, Lie KI, Wellens HJJ, eds. Lipid-lowering therapy and progression of coronary atherosclerosis. Vol. 180. London: Kluwer Academic, 1996:203-13.
29. Canner PL, Thompson B, Knatterud GL, Geller N, Campeau L, Zucker D. An application of the Zucker-Wittes modified ratio estimate statistic in the POST CABG Clinical Trial. Control Clin Trials (in press).
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
32. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:83.
33. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
34. National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-445.